Source:http://linkedlifedata.com/resource/pubmed/id/21388139
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
7
|
pubmed:dateCreated |
2011-4-7
|
pubmed:abstractText |
The DNA gyrase inhibitor cyclothialidine had been shown to be a valuable lead structure for the discovery of new antibacterial classes able to overcome bacterial resistance to clinically used drugs. Bicyclic lactone derivatives containing in their 12-14-membered ring a thioamide functionality were reported previously to exhibit potent antibacterial activity against gram-positive bacteria. Moderate in vivo efficacy, however, was demonstrated only for derivatives bearing hydrophilic substituents, which were found to have a favorable impact on pharmcokinetics, and to reduce metabolic degradation, in particular glucuronidation. The incorporation of an additional amide unit into the 14-membered monolactam-lactone scaffold of cyclothialidine analogues provided a new "dilactam" subclass of DNA gyrase inhibitors of inherently higher polarity. After adjusting their lipophilicity by methyl-halogen exchange at the benzene ring, compounds of this series did not require the thioamide functionality to exert a decent antibacterial potency and consequently exhibited improved pharmacokinetic properties resulting in a pronounced in vivo efficacy in a mouse septicaemia infection model.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Anti-Bacterial Agents,
http://linkedlifedata.com/resource/pubmed/chemical/DNA Gyrase,
http://linkedlifedata.com/resource/pubmed/chemical/Enzyme Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Lactams,
http://linkedlifedata.com/resource/pubmed/chemical/Lactones,
http://linkedlifedata.com/resource/pubmed/chemical/Peptides, Cyclic,
http://linkedlifedata.com/resource/pubmed/chemical/cyclothialidine
|
pubmed:status |
MEDLINE
|
pubmed:month |
Apr
|
pubmed:issn |
1520-4804
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:day |
14
|
pubmed:volume |
54
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
2207-24
|
pubmed:meshHeading |
pubmed-meshheading:21388139-Animals,
pubmed-meshheading:21388139-Anti-Bacterial Agents,
pubmed-meshheading:21388139-Bacteria,
pubmed-meshheading:21388139-DNA Gyrase,
pubmed-meshheading:21388139-Enzyme Inhibitors,
pubmed-meshheading:21388139-Lactams,
pubmed-meshheading:21388139-Lactones,
pubmed-meshheading:21388139-Mice,
pubmed-meshheading:21388139-Microbial Sensitivity Tests,
pubmed-meshheading:21388139-Models, Molecular,
pubmed-meshheading:21388139-Peptides, Cyclic,
pubmed-meshheading:21388139-Protein Conformation
|
pubmed:year |
2011
|
pubmed:articleTitle |
A new DNA gyrase inhibitor subclass of the cyclothialidine family based on a bicyclic dilactam-lactone scaffold. Synthesis and antibacterial properties.
|
pubmed:affiliation |
F. Hoffmann-La Roche Ltd., Discovery Chemistry, CH-4070 Basel, Switzerland.
|
pubmed:publicationType |
Journal Article
|